Cumulative Incidence of Ovarian Cancer to Given Age
	BRCA1		BRCA2		BRCA1/2
Population	50 yr	70 yr	50 yr	70 yr	50 yr	70 yr
Incidence of second cancers after breast cancer
—33 BRCA1-linked families (BCLC) [55]	29%	44%
—BRCA1-linked families (BCLC) [56]	29%	44%
Linkage analysis - maximization of LOD score
—BRCA1-linked families (BCLC) [56]	23%	63%
—237 breast and breast-ovarian cancer families (BCLC) [58]			0%	27%
Kin cohort
—Community-based Washington, D.C. area Jews, 61 BRCA1, 59 BRCA2 [46]	8%	16%	5%	18%	7%	16%
—Unselected cases ovarian cancer, 39 BRCA1, 21 BRCA2 [42]		36%a		10%a
Second or contralateral cancer incidence; focus was on nonbreast and ovary outcomes
—173 breast-ovarian cancer families either BRCA2-positive or BRCA2-linked (BCLC) [12]			3%	16%
Modified segregation analysis (MENDEL)
—Breast cancer cases, aged <55 years, 8 BRCA1, 16 BRCA2 [62]	11%	36%	3%	10%	4%	16%
—Families with 2+ cases ovarian cancer, 40 BRCA1, 11 BRCA2 [63]	17%	53%	1%	31%
—Unselected cases ovarian cancer, 12 BRCA1 [63]	21%	68%
—164 BRCA2-positive families from BCLC [66]				14%
—Unselected cases ovarian or breast cancer from 22 studies, 289 BRCA1, 221 BRCA2 [68]	13%	39%	1%	11%
Relative risk times population rates
—Jewish women with ovarian cancer, 44 BRCA1, 24 BRCA2 [64]		>40%b		20%b
—Unselected cases ovarian or breast cancer from 22 studies, 289 BRCA1, 221 BRCA2 [67]	11%	37%	3%	21%
Direct Kaplan-Meier estimates restricted to relatives known to be mutation positive
—Unselected Jewish breast cancer patients from NY, 67 BRCA1, 37 BRCA2 [43]	21%	46%	2%	12%
Mendelian retrospective likelihood approach
—U.S.-based through the Cancer Genetics Network, most counseling clinic-based, although smaller number population-based, 238 BRCA1, 143 BRCA2 [70]		40%		22%

LOD = logarithm of the odd

aIncidence to age 80 years

bIncidence to age 75 years

References

12. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91 (15): 1310-6, 1999.  [PUBMED Abstract]
    
    
42. Risch HA, McLaughlin JR, Cole DE, et al.: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 (3): 700-10, 2001.  [PUBMED Abstract]
    
    
43. King MC, Marks JH, Mandell JB, et al.: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (5645): 643-6, 2003.  [PUBMED Abstract]
    
    
46. Struewing JP, Hartge P, Wacholder S, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 (20): 1401-8, 1997.  [PUBMED Abstract]
    
    
55. Ford D, Easton DF, Bishop DT, et al.: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343 (8899): 692-5, 1994.  [PUBMED Abstract]
    
    
56. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56 (1): 265-71, 1995.  [PUBMED Abstract]
    
    
58. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (3): 676-89, 1998.  [PUBMED Abstract]
    
    
62. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 83 (10): 1301-8, 2000.  [PUBMED Abstract]
    
    
63. Antoniou AC, Gayther SA, Stratton JF, et al.: Risk models for familial ovarian and breast cancer. Genet Epidemiol 18 (2): 173-90, 2000.  [PUBMED Abstract]
    
    
64. Moslehi R, Chu W, Karlan B, et al.: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66 (4): 1259-72, 2000.  [PUBMED Abstract]
    
    
66. Thompson D, Easton D; Breast Cancer Linkage Consortium.: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68 (2): 410-9, 2001.  [PUBMED Abstract]
    
    
67. Satagopan JM, Boyd J, Kauff ND, et al.: Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8 (12): 3776-81, 2002.  [PUBMED Abstract]
    
    
68. Antoniou A, Pharoah PD, Narod S, et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 (5): 1117-30, 2003.  [PUBMED Abstract]
    
    
70. Chen S, Iversen ES, Friebel T, et al.: Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24 (6): 863-71, 2006.  [PUBMED Abstract]